Platelet deposition on eroded vessel walls at a stenotic shear rate is inhibited by lipid-lowering treatment with atorvastatin

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 7, 1999, Pages 1812-1817

  Alfon, José ^a   Royo, Teresa ^a   Garcia Moll, Xavier ^a   Badimon, Lina ^a,b  

^a CSIC   (Spain)

^b Cardiovascular Unit   (Spain)

Author keywords

Atorvastatin; HMG CoA; Platelet deposition; Reductase inhibitors; Vessell wall

Indexed keywords

ATORVASTATIN;

ANIMAL EXPERIMENT; ARTICLE; CORONARY ARTERY OBSTRUCTION; DRUG EFFECT; NONHUMAN; PRIORITY JOURNAL; SHEAR RATE; SWINE; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; VASCULAR ENDOTHELIUM;

EID: 0033038535     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.7.1812     Document Type: Article

References (24)

1. Vaugham CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet. 1996;348:1079-1082.
2. Negre-Aminou P, van Vliet AK, van Erck M, van Thiel GC, van Leeuwen RE, Cohen LH. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors: comparison with other human cell types. Biochim Biophys Acta. 1997;1345:259-268.
3. Llorente-Cortes V, Martinez-Gonzalez J, Badimon L. Esterified cholesterol accumulation induced by aggregated LDL uptake in human smooth muscle is reduced by HMG-CoA reductase inhibitors. Arterioscler Thromb Vasc Biol. 1998;18:738-746.
4. Hussein O, Rosenblat M, Schezinger S, Keidar S, Aviram M. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets. Br J Clin Pharmacol. 1997;44:77-83.
5. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz DL, Lupien P-J, Jones PH, Haber HE, Black DM. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 1995;15:678-682.
6. Ooi TC, Heinonen T, Alaupovic P, Davignon J, Lawrence L, Lupien PJ, Sniderman AD, Tan MH, Tremblay G, Sorisky A, Shurzinske L, Black DM. Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate. Arterioscler Thromb Vasc Biol. 1997;17:1793-1799.
7. Alfon J, Pueyo C, Badimon L. Regulation by atorvastatin, a novel HMG-CoA reductase inhibitor, of plasma lipids and thrombotic risk in atherosclerotic rabbits [abstract]. In: 66th Congress of the European Atherosclerosis Society Abstract Book; July 13-17, 1996; Florence. Italy. 1996:201.
8. Lipid Research Clinics Program. Manual of Laboratory Operations. Washington, DC: Dept of Health, Education and Welfare: 1975. DHEW publication No. NIH75-628.
9. Badimon L, Badimon JJ, Galvez A, Chesebro JH, Fuster V. Influence of arterial damage and wall shear rate on platelet deposition: ex vivo study in a swine model. Arteriosclerosis. 1986;6:312-320.
10. Badimon L, Turitto VT, Rosemark, Badimon JJ, Fuster V. Characterization of tubular flow chamber for studying platelet interaction with biological and prosthetic materials. J Lab Clin Med. 1987;6:706-718.
11. Mailhac A, Badimon JJ, Fernandez-Ortiz A, Meyer B, Chesebro JH, Fuster V, Badimon L. Effect of an eccentric severe stenosis on fibrin(ogen) deposition on severely damaged vessel wall in arterial thrombosis: relative contribution of fibrin(ogen) and platelets. Circulation. 1994;90:988-996.
12. Rand JH, Badimon L, Fuster V. The distribution of von Willebrand factor in porcine vascular endothelial cells varies with blood vessel type and location. Arteriosclerosis. 1987;7:287-291.
13. Gurr E. In: Biological Staining Methods. Buckinghamshire, UK: Searle Diagnostic Gurr Products: 1972:46.
14. Royo T, Vidal M, Badimon L. Porcine platelet von Willebrand antigen II (vW Ag II): inhibitory effect on collagen induced aggregation and comparative distribution with human platelets. Thromb Haemost. 1998;80: 677-685.
15. Bann AD, Hopkins J, Winkles J, Wainwright AC. Plasma and serum von Willebrand factor antigen concentrations in connective tissue disorders. Ann Clin Biochem. 1992;29:67-71.
16. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680-685.
17. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979;76:4350-4354.
18. Galvez A, Badimon L, Badimon JJ, Fuster V. Electrical blood from human, pig and rabbit. Thromb Haemost. 1986;56:128-132.
19. Royo T, Vidal M, Badimon L. Purification of the porcine platelet GP IIb-IIIa complex and the propolypeptide of von Willebrand factor. Thromb Haemost. 1998;80:302-309.
20. Read MS, Smith SV, Lamb MA, Brinkhous KM. Role of botrocetin in platelet agglutination: formation of an activated complex of botrocetin and von Willebrand factor. Blood. 1989;15:1031-1035.
21. Weiss HJ, Turitto VT, Baumgartner HR. Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. I: shear-rate dependent decrease of adhesion in von Willebrand's disease and the Bernard-Soulier syndrome. J Lab Clin Med. 1973;5:167-179.
22. Badimon L, Badimon JJ, Rand J, Turitto VT, Fuster V. Platelet deposition on von Willebrand Factor deficient vessels: extracorporeal perfusion studies in swine with von Willebrand's disease using native and heparinized blood. J Lab Clin Med. 1987;110:634-647.
23. Badimon L, Badimon JJ, Chesebro JH, Fuster V. von Willebrand factor and cardiovascular disease. Thromb Haemost. 1993;70:111-118.
24. Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Hugh P, Barrett P, Newton RS, Huff MW. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs. Arterioscler Thromb Vasc Biol. 1997;17:2589-2600.